Jasminellecontinu (Drospirenone, Ethinylestradiol | Lactose Monohydrate)

The combination works by suppressing the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), which blocks ovulation. Drospirenone also thickens cervical mucus and alters the endometrial lining, while ethinylestradiol stabilises the lining, together creating conditions that prevent fertilisation and implantation.

The dosing regimen is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule and duration should follow the prescriber’s instructions.

Jasminellecontinu is contraindicated during pregnancy (Category X) and must not be used by pregnant women. It is also not recommended for breastfeeding because hormonal contraceptives can affect milk production and infant exposure; alternative methods should be discussed with a clinician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Jasminellecontinu contains drospirenone, a progestin with anti‑androgenic and mild diuretic properties, which may offer benefits such as reduced water retention and potential improvement in acne compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other approved combined pills, while the safety profile follows the class‑wide considerations for estrogen‑progestin products.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and keep out of reach of children. Do not use tablets that are discoloured or past the expiry date.

Jasminellecontinu is taken orally. Swallow one tablet whole with water at the same time each day, preferably with or without food. If a dose is missed, follow the specific guidance provided in the patient information leaflet or by a healthcare professional.

The most serious risks include venous thromboembolism, arterial thrombosis (such as stroke or myocardial infarction), severe hypertension, and rare severe allergic reactions. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should discuss these risks with their prescriber.

Jasminellecontinu should not be used by women who are pregnant, have a known history of thromboembolic disease, uncontrolled hypertension, certain liver disorders, breast cancer, or estrogen‑dependent tumours. It is also contraindicated in smokers over 35 years of age and in individuals with known hypersensitivity to any component of the tablet.